Mereo BioPharma Group plc specializes in developing therapies for rare diseases, chiefly setrusumab for osteogenesis imperfecta and alvelestat for alpha-1 antitrypsin deficiency lung disease. The company remains pre-commercial, generating modest revenue from licensing and collaborations but continues to operate at significant losses driven by its R&D expenditure. Strong liquidity extends into mid-2027, yet sustaining development requires raising additional capital while navigating clinical risks and Nasdaq listing pressures. Strategic manufacturing partnerships provide some operational leverage, but commercialization hinges on upcoming trial outcomes and regulatory approvals.